Navigation Links
Avanir Pharmaceuticals Announces Results for Phase II PRIME Study
Date:12/10/2013

ding statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new products domestically and internationally, including the risks and uncertainties associated with meeting the objectives of the study of AVP-786, and AVP-923, including, but not limited to, risks relating to the successful development of these investigational drugs, delays or failures in enrollment, or delays in the release of study results,  obtaining additional indications for commercially marketed products domestically and internationally, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of th
'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
2. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
3. Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
4. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
5. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
6. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
7. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
8. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
9. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
10. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
11. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 /CNW/ -   ... recalled after Health Canada tests confirmed it contains two ... (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... product from retail stores across Canada ... including for weight loss and increased energy. ...
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a leader ... first patient in its study for ischemic stroke ... Stroke Association, ischemic strokes account for 87 percent ... qualified patients in the study, entitled "Internal Research ... Allogeneic Mesenchymal Stem Cells and Intrathecal Administration of ...
(Date:12/24/2014)... -- Actavis plc (NYSE: ACT ) today ... response letter from the U.S. Food and Drug ... for the fixed-dose combination (FDC) of nebivolol and ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... a complete response letter, Actavis remains committed to ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... Nov. 3, 2011 Dyadic International, Inc. ("Dyadic") ... on the discovery, development, manufacture and sale of ... enzyme and biopharmaceutical industries, today announced financial results ... (Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO) The financial information ...
... VIVUS, Inc. (NASDAQ: VVUS ) today announced that ... the peer-reviewed journal of The Obesity Society. The EQUIP study ... 1,267 severely obese (BMI >/= 35 kg/m 2 ) patients across ... of 14.4% of initial body weight among those who completed the ...
Cached Medicine Technology:Dyadic International Reports 2011 Third Quarter Financial Results 2Dyadic International Reports 2011 Third Quarter Financial Results 3Dyadic International Reports 2011 Third Quarter Financial Results 4Dyadic International Reports 2011 Third Quarter Financial Results 5Dyadic International Reports 2011 Third Quarter Financial Results 6Dyadic International Reports 2011 Third Quarter Financial Results 7Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... 2014 This is a professional and ... Sterilizers industry with a focus on the Chinese market. ... of the Sterilizers manufacturers and is a valuable source ... in the industry. This report provides a basic overview ... technology. In this part, the report presents the company ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... U.S. has enough capacity for typical season; experts less sure ... The current swine flu outbreak is raising critical questions about ... the logistics of getting it to the people who need ... cut into this fall,s production of seasonal influenza vaccine, experts ...
... 2nd Annual Disability Leadership & Policy Summit: ... to promote an exchange of ideas between people with disabilities ... health and human service professionals will convene on Wednesday, June ... speakers and their topics include: , , ...
... own, while most Americans agree both are equally ... has contributed to poorer overall family health and ... to healthcare. Two-thirds of Americans (66 percent) believe ... care of their health and their children,s health. ...
... Costs by Reducing UtilizationCOLUMBUS, Ohio, May 18 As ... healthcare costs, Quantum Health, Inc. announced that its Coordinated ... employee, or 14%, in 2008. Over the past ten ... to 4%-5% with no reduction in benefits or cost-shifting ...
... to improve navigation, functionality and user-friendliness. The new website still ... with better design and navigation, users can now access information, ... ... Neptune Beach, FL (PRWEB) May 18, 2009 ...
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
Cached Medicine News:Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:United Spinal Association's 2nd Annual Disability Leadership & Policy Summit: Health Issues and People with Disabilities 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents Than Children 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents Than Children 3Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 2Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 3Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 4Health News:International Student Insurance Announces Website Redesign 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: